FDA finalizes a 15-year-old sameness map for orphan MAbs
Drugmakers hoping to compete with a monoclonal antibody (MAb) granted a seven-year orphan drug exclusivity have final guidance on what they need to do to differentiate their MAbs to get around the exclusivity.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter